South Africa Cell And Gene Therapy Cdmo Market Size & Outlook
The cell and gene therapy cdmo market in South Africa is expected to reach a projected revenue of US$ 64.7 million by 2033. A compound annual growth rate of 14.4% is expected of South Africa cell and gene therapy cdmo market from 2025 to 2033.
South Africa cell and gene therapy cdmo market highlights
The South Africa cell and gene therapy cdmo market generated a revenue of USD 19.3 million in 2024 and is expected to reach USD 64.7 million by 2033.
The South Africa market is expected to grow at a CAGR of 14.4% from 2025 to 2033.
In terms of segment, pre-clinical was the largest revenue generating phase in 2024.
Pre-clinical is the most lucrative phase segment registering the fastest growth during the forecast period.
Cell and gene therapy cdmo market data book summary
Market revenue in 2024
USD 19.3 million
Market revenue in 2033
USD 64.7 million
Growth rate
14.4% (CAGR from 2025 to 2033)
Largest segment
Pre-clinical
Fastest growing segment
Pre-clinical
Historical data
2021 - 2023
Base year
2024
Forecast period
2025 - 2033
Quantitative units
Revenue in USD million
Market segmentation
Pre-clinical, Clinical
Key market players worldwide
Lonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc
Other key industry trends
In terms of revenue, South Africa accounted for 0.4% of the global cell and gene therapy cdmo market in 2024.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Middle East & Africa, Saudi Arabia cell and gene therapy cdmo market is projected to lead the regional market in terms of revenue in 2033.
UAE is the fastest growing regional market in Middle East & Africa and is projected to reach USD 56.9 million by 2033.
South Africa cell & gene therapy CDMO market is expected to witness considerable growth due to the increasing demand for biologics, rising initiatives by biopharmaceutical companies, and the presence of a diverse population in the country.
In addition, the availability, affordability, accessibility, and quality of generic products & biologics in South Africa are anticipated to fuel market growth during the forecast period. However, slow economic growth & development of the healthcare system, imports of APIs, and potentially rising prices of key medicines in the country are anticipated to impede market growth in the coming decade.
Furthermore, in the country, the research industry complies with the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) & FDA standards. The diverse population & cost-effective trials are some of the primary drivers of the cell and gene therapy CDMO market.
South Africa Cell And Gene Therapy CDMO Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cell And Gene Therapy CDMO Market Outlook will help companies and investors design strategic landscapes.
Pre-Clinical was the largest segment with a revenue share of 75.13% in 2024.
Horizon Databook has segmented the South Africa cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2021 to 2033.
South Africa cell & gene therapy CDMO market is expected to witness considerable growth due to the increasing demand for biologics, rising initiatives by biopharmaceutical companies, and the presence of a diverse population in the country.
In addition, the availability, affordability, accessibility, and quality of generic products & biologics in South Africa are anticipated to fuel market growth during the forecast period. However, slow economic growth & development of the healthcare system, imports of APIs, and potentially rising prices of key medicines in the country are anticipated to impede market growth in the coming decade.
Furthermore, in the country, the research industry complies with the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) & FDA standards. The diverse population & cost-effective trials are some of the primary drivers of the cell and gene therapy CDMO market.
South Africa Cell And Gene Therapy Cdmo Market Phase Outlook (Revenue, USD Million , 2021-2033)
Pre-clinical
Clinical
South Africa Cell And Gene Therapy Cdmo Market Indication Outlook (Revenue, USD Million , 2021-2033)
Rare Diseases
Others
Oncology
Infectious Diseases
Neurological disorders
South Africa Cell And Gene Therapy Cdmo Market Product Type Outlook (Revenue, USD Million , 2021-2033)
Gene Therapy
Gene-Modified Cell Therapy
Cell Therapy
Reasons to subscribe to Cell And Gene Therapy CDMO Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cell And Gene Therapy CDMO Market Outlook databook
Our clientele includes a mix of Cell And Gene Therapy CDMO Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the South Africa Cell And Gene Therapy CDMO Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into South Africa Cell And Gene Therapy CDMO Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
South Africa Cell And Gene Therapy Cdmo Market, 2021-2033 (US$M)